News

WASHINGTON, D.C. – Yesterday, Congressman Morgan Griffith (VA-09), Chairman of the Subcommittee on Health, led a markup of several public health reauthorization bills. “As we must do with every authorization bill that moves through this committee, it is critical that we evaluate the impacts these programs have had, and not only ensure the money is being spent as it was originally intended, but also ensure patient privacy is protected ,” said Chairman Griffith. “ Considering each of these reauthorizations is an important step forward to ensure each program is working as intended, and we will continue to examine these programs as we move to full committee .” Legislative Vote Summary: H.R. 4262 , To reauthorize programs related to health professions education, and for other purposes, was reported to the full committee by a voice vote. H.R. 3593 , Title VIII Nursing Workforce Reauthorization Act of 2025, was reported to the full committee by a voice vote. H.R. 2493 , Improving Care in Rural America Reauthorization Act of 2025, was reported to the full committee by a voice vote. H.R. 3419 , To amend the Public Health Service Act to reauthorize the telehealth network and telehealth resource centers grant programs, was reported to the full committee by a voice vote. H.R. 3302 ,  Healthy Start Reauthorization Act of 2025, was reported to the full committee by a voice vote. H.R. 2846 , To amend title II of the Public Health Service Act to include as an additional right or privilege of commissioned officers of the Public Health Service (and their beneficiaries) certain leave provided under title 10, United States Code to commissioned officers of the Army (or their beneficiaries), was reported to the full committee by a voice vote. H.R. 4709 ,  Newborn Screening Saves Lives Reauthorization Act of 2025, was reported to the full committee by a voice vote Watch the full markup here . Below are key excerpts from today’s markup: Congressman Buddy Carter (GA-01) on the To amend the Public Health Service Act to reauthorize the telehealth network and telehealth resource centers grant programs : “This bill reauthorizes the telehealth network and telehealth resource centers grant programs, administered by the Health Resources and Services Administration. These programs aim to improve access to telehealth services by providing technical assistance and other support methods to providers in rural and frontier communities, so patients in these areas can more easily access necessary telehealth services. Approximately 22,000 patients across the country have benefited from these programs. We must continue these vital resources to help improve health outcomes in underserved communities.” Chairman John Joyce (PA-13) on the Improving Care in Rural America Reauthorization Act of 2025: “The Improving Care in Rural America [Reauthorization Act] is legislation that accomplishes something that is so important for the constituents that don't have that access to screening, that don't have that access to care, and it is important that we reauthorize this. Representative Carter, in his legislation, understands that rural America is often left behind. This is a bipartisan piece of legislation that addresses that issue, that understands that we have a responsibility to all of our constituents, to all of America.”

WASHINGTON, D.C.  – Congressman Buddy Carter (GA-01), Chairman of the Subcommittee on Health, delivered the following opening statement at today’s hearing titled  The Fiscal Year 2026 Department of Health and Human Services Budget Subcommittee Chairman Carter's opening statement as prepared for delivery: “It is my pleasure to begin today’s hearing by welcoming the Secretary of Health and Human Services Robert F. Kennedy, Jr. to the House Energy and Commerce Committee Subcommittee on Health.  “Thank you, Secretary Kennedy, for coming before the Committee to discuss the Fiscal Year 2026 budget for the U.S. Department of Health an d Human Services.  “ In 2023, our nation spent an estimated $4.9 trillion on health care. That’s nearly 20 percent of our Gross Domestic Product. And when it comes to per-person health care spending, the United States far surpasses every other nation in the world.  “ And yet, America’s health outcomes still lag behind our peers. Life expectancy in the U.S. is lower than in other developed economies, and rates of infant and maternal mortality, obesity, diabetes, and heart disease are higher. At the same time, public trust in government health agencies has eroded.  “ The results of our record-breaking spending speak for themselves — and they’re unacceptable.   “ The system isn’t just expensive — it’s failing the very people it’s meant to serve.  “ Currently, in the United States, three in four adults experience one or more chronic conditions. In 2013, no state had adult obesity prevalence at or above 35 percent. Fast forward to 2023, 23 states had 35 percent or higher adult obesity rates. According to the CDC, in my home state of Georgia, 35 percent of adults are obese, and one in ten adults are living with three or more chronic conditions.    “ During my time as a pharmacist, I saw first-hand the toll that diet-related chronic diseases can have on individuals and families, due to rising health care premiums, out-of-pocket-costs, and missed work. The financial impact is astronomical – not to mention how taxing the physical, emotional, and mental burdens can be.   “ Just looking at the impact of diabetes, the United States spends more than $327 billion each year combatting the disease–with $237 billion spent on medical costs and another $90 billion in productivity losses.  “ America needs a new prescription — a clear, bold vision for the future. We can no longer afford to simply throw more money at this problem and hope for change. It is time to break from the old ways and embrace innovative, courageous ideas that will truly Make America Healthy Again.  “ I am looking forward to hearing more about how HHS is working to improve health care access for American patients and reduce provider burnout by leading on necessary changes to fix the broken health insurance prior authorization process.  “ I am also looking forward to hearing more about your agency’s plan to reduce unnecessary animal testing. So many of us here today are committed to a more efficient drug development process, and I am encouraged by the FDA’s Roadmap to reduce animal testing in preclinical safety studies through the use of innovative 21st-century science. “ As a supporter of the FDA Modernization Act 2.0 and the lead author of the FDA Modernization Act 3.0, I am excited to see that, under your leadership, the Department of Health and Human Services is building off of these proposals and leading the charge for the development of safe, effective treatments and therapies without unnecessary animal suffering. “ I look forward to hearing additional details of the Secretary’s proposal, and to continuing the dialogue between HHS and the Energy and Commerce Committee as we begin the budget process in earnest.  “ Again, I appreciate you being here today. I look forward to hearing how the proposed HHS budget will advance President Trump’s mission of Making America Healthy Again." ###

WASHINGTON, D.C. – Today, Congressman Buddy Carter (GA-01), Chairman of the Subcommittee on Health, led a hearing titled The Fiscal Year 2026 Department of Health and Human Services Budget. “America needs a new prescription — a clear, bold vision for the future. We can no longer afford to simply throw more money at this problem and hope for change,” said Chairman Carter . “It is time to break from the old ways and embrace innovative, courageous ideas that will truly Make America Healthy Again.” Watch the full hearing here . Below are key excerpts from today’s hearing: Congressman Gus Bilirakis (FL-09): “One important tool in promoting drug development is the FDA's Rare Pediatric Disease Designation and Priority Review Voucher Program, which has led to the approval of over 50 treatments for 39 different rare, pediatric diseases - 36 of which had no FDA approval treatments before the program began. I was very pleased to see the president's FDA budget allocate funding for this priority review voucher program, and I have bipartisan legislation that would fully reauthorize the program for years to come.” Congresswoman Mariannette Miller-Meeks (IA-02): “I was just wondering if you can explain how HHS will be investing in rural America and specifically rural Iowa to ensure that Americans still have access to vital health care services.” Secretary Kennedy: “ We have a number of programs for expanding healthcare in rural areas. One of those that I'm most excited about are these innovations in telemedicine and AI nursing. That is going to deal with some of the treatment [and] the diagnosis issues. I've seen the systems in action, and they're extraordinary.” Congresswoman Kat Cammack: (FL-03): “Under the previous administration of Joe Biden, maternal health deserts expanded significantly, leaving over 2.5 million women without access to any sort of maternal health care. In fact, I believe it was 1 in 25 maternal health clinics [that] closed under the previous administration. And you've pointed out that there are more than 40 different maternal health programs scattered across HHS. From where I sit, that sounds like a lot of bureaucracy, and I want us to focus on patient outcomes and improving those, like you do.” ###

WASHINGTON, D.C. – Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, along with Reps. Palmer (AL-06), Carter (GA-01), Bilirakis (FL-12), and Obernolte (CA-23), penned a letter to the Executive Director of Covered California (CoveredCA), Jessica Altman, to request further information related to the potentially unauthorized transmission of sensitive personal health information involving Covered California’s website. Key Letter Excerpt: “According to public reports and agency statements, tracking technology was embedded on Covered California's website beginning in February 2024, as part of a broader digital advertising effort, and in direct contravention of the tracking platform’s user agreement, which prohibits the use of such tools on pages that collect sensitive health information. Although the tags were reportedly removed in April 2025, following external scrutiny and a vendor transition, the extended period of data exposure raises serious questions about the adequacy of safeguards that Covered California had in place. Forensic testing by investigative reporters identified the trackers in operation and confirmed that user-entered health information was being transmitted to third parties without consent. These circumstances warrant examination of Covered California’s actions under federal privacy standards.” “Ensuring the confidentiality of health information is a foundational obligation for entities operating within the health insurance ecosystem. Federal privacy protections, particularly the Health Insurance Portability and Accountability Act (HIPAA), establish expectations for how covered organizations handle sensitive data. Recent reports and public filings raised questions about whether those expectations were met in this case, and whether existing oversight mechanisms are sufficient to detect and prevent improper disclosures.” Background: Forensic testing shows Covered California —the State of California’s official health insurance marketplace—has been sending sensitive user health data to third-party websites through several online data trackers. Prior to removal of the trackers, CoveredCA had more than 60 trackers active on its website; the average number of trackers on a government website is three. Some types of information sent to such websites include: Searches for doctors in network with specific plans/specializations Demographic information, including gender, ethnicity, and marital status Length of treatment a patent received by a provider Frequency of doctor visits If the user indicated they were blind, pregnant, a victim of domestic abuse, or used prescription medications. The State of California independently operates CoveredCA. As the state’s official ACA marketplace, CoveredCA falls under the purview of Health Insurance Portability and Accountability Act (HIPAA). The disclosure of information such as pregnancy or prescription drug use without proper consent—even for “marketing purposes”—may violate HIPAA. This Congress, the Committee has sent letters to 23andMe and DeepSeek over potential data privacy concerns: The Committee also held a hearing last Congress on the Change Healthcare hack, where personal health information was also jeopardized. CLICK HERE to read Fox News coverage of the letter. CLICK HERE to view the full letter. ###

WASHINGTON, D.C. – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, and Congressman Buddy Carter (GA-01), Chairman of the Subcommittee on Health, announced a hearing titled The Fiscal Year 2026 Department of Health and Human Services Budget . “The recent passage of the OBBBA was an incredible example of how we are strengthening, securing, and sustaining our government health programs under President Trump,” said Chairmen Guthrie and Carter. “ Next week’s hearing gives us the opportunity to examine ways in which we can further incorporate health innovation, expand access to affordable care, and make America healthy again.” Subcommittee on Health hearing titled The Fiscal Year 2026 Department of Health and Human Services Budget WHAT: Subcommittee on Health hearing on Department of Health and Human Services FY26 Budget. DATE: Tuesday, June 24, 2025 TIME: 10:00 AM ET LOCATION: 2123 Rayburn House Office Building This notice is at the direction of the Chairman. The hearing will be open to the public and press and will be livestreamed online at energycommerce.house.gov . If you have any questions concerning this hearing, please contact Annabelle Huffman at Annabelle.Huffman@mail.house.gov . If you have any press-related questions, please contact Katie West at Katie.West@mail.house.gov . ###

WASHINGTON, D.C. – Today, Congressman Earl L. "Buddy Carter" (GA-01), Chairman of the Subcommittee on Health, led a hearing titled Made in America: Strengthening Domestic Manufacturing and Our Health Care Supply Chain. “Under the leadership of President Trump, we are bringing manufacturing back to America,” said Chairman Carter. “ Since the start of this year – the start of President Trump’s second term – Johnson & Johnson broke ground on a new $2 billion facility in North Carolina, Amgen announced a $900 million manufacturing expansion in Ohio, AbbVie committed $10 billion to invest in the United States, and Sanofi announced plans to invest at least $20 billion. And these are just a few examples; this is just the start.” Watch the full hearing here . Below are key excerpts from today’s hearing: Congressman Buddy Carter (GA-01): “If Congress were to act on the recommendations today, how quickly could our domestic capacity expand? If we were to act on this, how quickly can we get this up and running?” Mr. Cashman: “With the right policy framework, we could significantly expand production with 18 to 24 months. We're currently running three active production lines; we have two crews on first shift and another crew on second shift. By simply adding new crews, to adding shifts so we can have three shifts per day on each line, we could dramatically increase our production.” Congressman Troy Balderson (OH-12): “ We know that a recent analysis showed that around half of the active pharmaceutical ingredients (APIs) for prescription medications in the U.S come from India and the EU. With around 12 percent being manufactured domestically here in the U.S. from your perspective and with your great experience, how do you believe we can increase the share in a sustainable way?” Dr. Piervincenzi: “I think the first layer is to increase the production of API, [which] will require new facilities and substantial new investments and time. There are shorter term ways to bridge the gap and to create a more secure supply chain, including through friend shoring and other purchasing opportunities. And finally, also considering the potentially even higher vulnerability to the starting materials upstream of the APIs, which may be even more highly concentrated in adversary countries and coming to the U.S. through India and Europe.” Congressman Jay Obernolte: (CA-23): “One of the things [Mr. Cashman] suggested was long-term supply contracts, but if you are someone that has consistent demand for a drug like amoxicillin, and you've experienced a situation where supply is constrained and therefore the market reacts by raising prices up to astronomical levels, you would think that would incentivize you, just from a financial perspective, to diversify your supply chains.”

WASHINGTON, D.C.  – Congressman Buddy Carter (GA-01), Chairman of the Subcommittee on Health, delivered the following opening statement at today’s hearing titled  Made In America: Strengthening Domestic Manufacturing And The Health Care Supply Chain. Subcommittee Chairman Carter's opening statement as prepared for delivery: “Today’s hearing is critical in addressing our nation’s reliance on adversarial countries for essential medications and health care products. This dependence not only jeopardizes our national security and patient safety, but also highlights the urgent need to increase domestic and friend-shored manufacturing. “Let me be clear: the United States should never be dependent on the Chinese Communist Party for the antibiotics and essential medicines. But that’s exactly the dangerous position we are in today. “In 2002, the United States manufactured 72 percent of the pharmaceuticals it consumed. By 2023, that number had dropped to just 37.5 percent. We didn’t just outsource manufacturing—we outsourced the sovereignty and safety of our health care system. “We saw the impacts of this reliance firsthand during the COVID-19 pandemic. According to a conversation I had with the Administration for Strategic Preparedness and Response, or ASPR, under the Trump Administration, the United States saw a downtick in the amount of PPE and pharmaceuticals coming to our country from China in the fall of 2019. We didn’t learn about COVID-19 until January 2020. “China knew there was an unidentified sickness in its own country, concealed it, and then withheld medical supplies so the United States was less prepared when COVID-19 hit our shores. “As both a pharmacist and a member of Congress, I know how critical these medicines and supplies are — especially for our national security. Under the Biden-Harris Administration, over 323 drugs were in shortage during the first quarter of 2024 – an all-time high – and cancer patients were often forced to switch treatments, adjust dosage regimens, or, in extreme cases, unable to receive their lifesaving medications. There was no comprehensive effort to support American manufacturers or reduce our reliance on foreign supply chains. “That is unacceptable. “Thankfully, President Trump is taking meaningful action by demanding real investment in our domestic production base and putting an end to decades of failed “America Last” policies that left our supply chains hollowed out and put our patients, constituents, and families at risk. “Under the leadership of President Trump, we are bringing manufacturing back to America. Since the start of this year – the start of President Trump’s second term – Johnson & Johnson broke ground on a new $2 billion facility in North Carolina, Amgen announced a $900 million manufacturing expansion in Ohio, AbbVie committed $10 billion to invest in the United States, and Sanofi announced plans to invest at least $20 billion.  “And these are just a few examples. This is just the start.  “I look forward to hearing from my other colleagues about the recent investments in their Districts and States during this hearing today, and I am thrilled to see what additional investments continue to flow and thrive under an Administration focused on unleashing innovation and bringing capacities back home.  “Along those lines, I commend recent efforts by this Administration to bolster domestic production, but we must do our part in Congress as well. This hearing will make it clear that more can be done to eliminate burdensome regulatory barriers, streamline processes that impede our competitiveness on the global stage, and establish the proper incentives to ensure we are creating the environment to allow innovation to flourish.  “It is no coincidence that Georgia – the No. 1 state in the nation to do business – is home to Manus Bio, who has invested nearly $60 million and created over 100 jobs with the acquisition of a new manufacturing facility in Augusta. We need more policies at the federal level that mirror the pro-growth examples we have in the state of Georgia.  “That is why House Republicans passed the One Big Beautiful Bill Act, which incentivizes domestic medical supply production by rewarding companies that build their products in America, like USAntibiotics, who is the last remaining end-to-end domestic U.S. manufacturer of amoxicillin, the most prescribed antibiotic in the country.  This is about protecting American lives, empowering American workers, restoring American sovereignty, and reinforcing U.S. leadership in medical innovation. “China is not our friend. Every product component that then turns into a vial of medicine or a piece of medical equipment that is made in China is a missed opportunity to strengthen our economy and protect our people. “It is time to act. We need to view pharmaceutical and health care supply chain independence just as we are viewing energy independence. I am proud to stand with President Trump and all those committed to putting America First in our health care system—starting with the medicines we rely on every day.” ###

WASHINGTON, D.C. – Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, and Congressman Buddy Carter (GA-01), Chairman of the Subcommittee on Health, announced a hearing titled Made in America: Strengthening Domestic Manufacturing and the Health Care Supply Chain .  “We have long been champions of policies that support efforts to onshore U.S.-based manufacturing and bolster our domestic supply chain, while, at the same time, strengthening our national security interests and economic goals,” said Chairmen Guthrie and Carter. “ Reducing America’s reliance on other nations for essential medications and health care products has been a long-standing priority of the Subcommittee on Health, and we look forward to examining the current challenges and opportunities to best incentivize and establish a reliable, safe, resilient, and efficient health care supply chain.”   Subcommittee on Health hearing titled Made in America: Strengthening Domestic Manufacturing and Our Health Care Supply Chain   WHAT: Subcommittee on Health hearing on Strengthening Domestic Manufacturing and the Health Care Supply Chain.  DATE: Wednesday, June 11, 2025  TIME: 10:00 AM ET  LOCATION: 2123 Rayburn House Office Building  This notice is at the direction of the Chairman. The hearing will be open to the public and press and will be livestreamed online at energycommerce.house.gov . If you have any questions concerning this hearing, please contact Annabelle Huffman at Annabelle.Huffman@mail.house.gov . If you have any press-related questions, please contact Katie West at Katie.West@mail.house.gov .   ###

WASHINGTON, D.C. – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, and Congressman Earl L. “Buddy” Carter, Chairman of the Subcommittee on Health, issued the following statement after Dr. Mehmet Oz was confirmed by the Senate to serve as Administrator of the Centers for Medicare and Medicaid Services (CMS). “CMS plays an integral role in ensuring Americans can access health care, particularly for seniors, pregnant women, children, and individuals with disabilities,” said Chairmen Guthrie and Carter . “Dr. Oz is an accomplished physician, an innovator, and a world-class communicator, who will help modernize the agency by utilizing new cutting-edge technology that empowers health care providers to better serve the American people. We look forward to partnering with him to improve health outcomes for Americans.” ###